| Structural highlights
2vv9 is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| | Ligands: |
| | NonStd Res: | |
| Related: | 1pye, 1h08, 2vth, 2b53, 1v1k, 1okv, 1h25, 1ke7, 1pxk, 2bhh, 2vta, 2uue, 1gz8, 1e1v, 1ol2, 1h27, 1jsv, 2b52, 1ke5, 1fin, 2c5o, 2c68, 2vtt, 1p2a, 2vtq, 2c4g, 1w0x, 1h1q, 1pxo, 1ke9, 2a0c, 1hck, 1jsu, 1pxn, 2uze, 2vtm, 2v0d, 1oiq, 1h1r, 2iw8, 1pw2, 1gih, 1hcl, 2vtn, 1jst, 1oiu, 1b38, 1pxm, 1fq1, 1vyw, 1h1p, 2c69, 1urc, 1pxi, 2c6i, 1ykr, 2uzd, 2c5y, 2c6k, 1wcc, 2j9m, 1vyz, 2vti, 1jvp, 1w98, 1pkd, 1p5e, 2vts, 2c5p, 2uzn, 2b54, 1pxj, 1ke6, 2uzl, 2cci, 2g9x, 2bkz, 1y91, 2iw6, 1gij, 1r78, 1h0v, 2iw9, 1w8c, 1buh, 2bpm, 2bts, 1fvv, 1okw, 2vtp, 2a4l, 2c6t, 1fvt, 1qmz, 2vu3, 1ogu, 2b55, 1pf8, 1h1s, 2c5v, 2jgz, 2bhe, 1urw, 1oiy, 2c6l, 1f5q, 2c6o, 2vtl, 1ol1, 1h01, 2uzb, 1oir, 1oi9, 2vtj, 2cjm, 2c5n, 2c5x, 2c6m, 1oit, 2v22, 1gy3, 1gii, 1di8, 1e9h, 2vto, 1dm2, 2uzo, 1h24, 1h00, 2exm, 2clx, 1pxp, 2cch, 1b39, 2btr, 1aq1, 1h0w, 1ckp, 1g5s, 1h28, 1ke8, 1pxl, 2vtr, 1h26, 1h07, 1e1x, 1y8y |
| Activity: | Cyclin-dependent kinase, with EC number 2.7.11.22 |
| Resources: | FirstGlance, OCA, RCSB, PDBsum |
Evolutionary Conservation
Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.
Publication Abstract from PubMed
A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been identified. The compounds exhibit excellent physiochemical properties and a novel binding mode, whereby a bridging interaction via a water molecule with Asp 86 of CDK2, leads to selectivity for the CDK family of enzymes over other kinases. Piperazines 2e and 2i were subsequently shown to inhibit tumour growth when dosed orally in a nude mouse xenograft study. Additional chemical series that exploit this unexpected interaction with Asp 86 are also described.
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.,Finlay MR, Acton DG, Andrews DM, Barker AJ, Dennis M, Fisher E, Graham MA, Green CP, Heaton DW, Karoutchi G, Loddick SA, Morgentin R, Roberts A, Tucker JA, Weir HM Bioorg Med Chem Lett. 2008 Aug 1;18(15):4442-6. Epub 2008 Jun 12. PMID:18617397[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Finlay MR, Acton DG, Andrews DM, Barker AJ, Dennis M, Fisher E, Graham MA, Green CP, Heaton DW, Karoutchi G, Loddick SA, Morgentin R, Roberts A, Tucker JA, Weir HM. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4442-6. Epub 2008 Jun 12. PMID:18617397 doi:10.1016/j.bmcl.2008.06.027
|
